Skip to main content
. Author manuscript; available in PMC: 2017 Jun 12.
Published in final edited form as: Ann Intern Med. 2010 May 18;152(10):621–629. doi: 10.7326/0003-4819-152-10-201005180-00002

Figure. Clinical strategies and progression model for prostate cancer.

Figure

ADT = androgen deprivation therapy; BMD = bone mineral density; PSA = prostate-specific antigen. Top. Algorithm showing a decision made at the onset of ADT for localized prostate cancer. Patients assigned to the alendronate group received alendronate for 5 years after proceeding to the prostate cancer progression model. Bottom. Prostate cancer progression model. Patients enter the model with localized disease. Each year, patients are at risk for the progression of prostate cancer, the occurrence of a hip fracture, or both. Throughout the patients’ lifetime, all patients are at risk for death from causes unrelated to prostate cancer (not shown by the state or arrows). Squares represent the health states in the model. Arrows represent transitions between health states.